肝细胞癌（LIHC）是一种恶性肿瘤，起源于肝细胞或肝内胆管上皮细胞，是全球常见的恶性肿瘤之一。更好地识别肝癌生物标志物已成为当前的挑战之一。虽然在各种人类实体癌症中，低氧诱导脂滴相关蛋白（HILPDA）已被报道与肿瘤进展关联，但在肝细胞癌领域中很少报道；因此，本文利用TCGA的RNA测序数据分析HILPDA和差异表达基因（DEG）的表达。此外，通过GO / KEGG，GSEA，免疫细胞浸润分析和蛋白质相互作用网络对HILPDA相关DEG的功能富集分析进行了研究。通过Kaplan-Meier Cox回归和预后数表模型计算了HILPDA在LIHC中的临床意义。使用R软件包分析联合研究。因此，与正常样品相比，HILPDA在包括LIHC在内的各种恶性肿瘤中高度表达，并且高表达HILPDA与不良预后有关（P <0.05）。Cox回归分析显示高HILPDA是一种独立的预后因素；年龄和细胞遗传风险被包括在预测数表预后模型中。共鉴定了1294个DEGs，其中1169个基因表达上调，125个基因表达下调。总之，HILPDA的高表达是LIHC不良结局的潜在生物标志物。 版权所有© 2023作者。 Wolters Kluwer Health，Inc. 发布。

Hepatocellular carcinoma (LIHC) is a malignant tumor arising from hepatocytes or intrahepatic bile duct epithelial cells, which is one of the common malignancies worldwide. Better identification of liver cancer biomarkers has become one of the current challenges. Although hypoxia inducible lipid droplet associated (HILPDA) has been reported to be associated with tumor progression in a variety of human solid cancers, it has rarely been reported in the field of hepatocellular carcinoma; therefore, in this paper, RNA sequencing data from TCGA were used to analyze the expression of HILPDA and differentially expressed genes (DEGs). In addition, functional enrichment analysis of HILPDA-associated DEGs was performed by GO/KEGG, GSEA, immune cell infiltration analysis and protein-protein interaction network. The clinical significance of HILPDA in LIHC was calculated by Kaplan-Meier Cox regression and prognostic nomogram models. R package was used to analyze the combined studies. Thus, HILPDA was highly expressed in various malignancies, including LIHC, compared with normal samples, and high HILPDA expression was associated with poor prognosis (P < .05). Cox regression analysis showed high HILPDA to be an independent prognostic factor; age and cytogenetic risk were included in the nomogram prognostic model. A total of 1294 DEGs were identified between the high and low expression groups, of which 1169 had upregulated gene expression and 125 had downregulated gene expression. Overall, high expression of HILPDA is a potential biomarker for poor outcome in LIHC.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.